Pay vs Performance Disclosure - USD ($)
Jan. 02, 2026
Jan. 03, 2025
Dec. 29, 2023
Dec. 30, 2022
Dec. 31, 2021
Value of Initial Fixed $100 Investment Based On: | Net Income (millions) ($) | Net Product Revenues (millions) ($)(5) | ||||||
Year | Summary Compensation Table Total for PEO ($)(1) | Compensation Actually Paid to PEO ($)(1)(2) | Average Summary Compensation Table Total for Non-PEO NEOs ($)(1) | Average Compensation Actually Paid to Non-PEO NEOs ($)(1)(2) | Total Stockholder Return ($)(3) | Peer Group Total Stockholder Return ($)(4) | ||
2025 | 33,239,183 | 55,131,172 | 9,093,339 | 5,300,849 | 217 | 125 | 782.6 | 2,122.8 |
2024 | 12,732,048 | 39,392,518 | 4,119,867 | 11,247,723 | 200 | 122 | 521.3 | 1,809.4 |
2023 | 16,423,307 | 31,702,754 | 5,505,198 | 7,804,316 | 141 | 121 | 207.8 | 1,628.9 |
2022 | 16,877,545 | 16,020,538 | 5,149,608 | 5,038,751 | 94 | 116 | 182.3 | 1,401.2 |
2021 | 7,530,431 | 15,297,662 | 3,510,384 | 5,612,040 | 107 | 129 | 231.1 | 1,077.3 |
as follows: (i) for 2025 Mr. Senner, Dr. Aftab, Mr. Haley, Dr. Hefti, Mr. Hessekiel and Dr. Peterson (ii) for 2024, Mr. Senner, Dr.
Aftab, Dr. Peterson and Mr. Hessekiel; (iii) for 2023, Mr. Senner, Dr. Aftab, Dr. Peterson, Mr. Hessekiel and Dr. Goodman; (iv) for
2022, Mr. Senner, Dr. Goodman, Mr. Haley and Mr. Hessekiel; (iv) for 2021, Mr. Senner, Mr. Haley, Mr. Hessekiel, Dr. Peter
Lamb and Dr. Gisela M. Schwab.
dividends for the measurement period, assuming dividend reinvestment, and (b) the difference between our share price at the
end and the beginning of the measurement period, by (ii) our share price at the beginning of the measurement period. The
beginning of the measurement period for each year in the table is January 1, 2021. Cumulative TSR is calculated assuming an
investment of $100 in our common stock on January 1, 2021.
(4) Represents the cumulative peer group TSR, weighted according to the respective companies’ stock market capitalization at the
beginning of each period for which a return is indicated. The peer group used for this purpose is the Nasdaq Biotechnology
Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our annual
reports for each of the years in the table.
the Summary Compensation Table to reflect the exclusion and inclusion of certain amounts for the PEO and the Non-PEO NEOs;
the tables set forth below reflect those adjustments. Equity values in the tables below are calculated in accordance with FASB
ASC Topic 718. Amounts in the “Exclusion of Stock Awards and Options Awards” column of the tables below are the totals from
the “Stock Awards” and “Option Awards” columns set forth in the Summary Compensation Table. The differences between the
amounts in the “Total” column of the Summary Compensation Table and the “compensation actually paid” are primarily
attributable to the appreciation in the price of our common stock and the annual vesting of RSU and earned PSU awards, as well
as the value recognized upon or following achievement of performance targets for the PSU awards during the year.
Year | Summary Compensation Table Total for PEO ($) | Exclusion of Stock Awards and Options Awards for PEO ($) | Inclusion of Equity Values for PEO ($) | Compensation Actually Paid to PEO ($) |
2025 | 33,239,183 | (30,539,552) | 52,431,541 | 55,131,172 |
Year | Average Summary Compensation Table Total for Non-PEO NEOs ($) | Average Exclusion of Stock Awards and Options Awards for Non-PEO NEOs ($) | Average Inclusion of Equity Values for Non-PEO NEOs ($) | Average Compensation Actually Paid to Non-PEO NEOs ($) |
2025 | 9,093,339 | (7,848,228) | 4,055,738 | 5,300,849 |
the Summary Compensation Table to reflect the exclusion and inclusion of certain amounts for the PEO and the Non-PEO NEOs;
the tables set forth below reflect those adjustments. Equity values in the tables below are calculated in accordance with FASB
ASC Topic 718. Amounts in the “Exclusion of Stock Awards and Options Awards” column of the tables below are the totals from
the “Stock Awards” and “Option Awards” columns set forth in the Summary Compensation Table. The differences between the
amounts in the “Total” column of the Summary Compensation Table and the “compensation actually paid” are primarily
attributable to the appreciation in the price of our common stock and the annual vesting of RSU and earned PSU awards, as well
as the value recognized upon or following achievement of performance targets for the PSU awards during the year.
Year | Summary Compensation Table Total for PEO ($) | Exclusion of Stock Awards and Options Awards for PEO ($) | Inclusion of Equity Values for PEO ($) | Compensation Actually Paid to PEO ($) |
2025 | 33,239,183 | (30,539,552) | 52,431,541 | 55,131,172 |
Year | Average Summary Compensation Table Total for Non-PEO NEOs ($) | Average Exclusion of Stock Awards and Options Awards for Non-PEO NEOs ($) | Average Inclusion of Equity Values for Non-PEO NEOs ($) | Average Compensation Actually Paid to Non-PEO NEOs ($) |
2025 | 9,093,339 | (7,848,228) | 4,055,738 | 5,300,849 |
the following tables:
Year | Year End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year for PEO ($) | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years for PEO ($) | Fair Value as of Vesting Date of Equity Awards Granted and Vested During Year for PEO ($) | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested During Year for PEO ($) | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for PEO ($) | Total – Inclusion of Equity Values for PEO ($) |
2025 | 35,083,767 | 14,039,301 | — | 3,308,473 | — | 52,431,541 |
Year | Average Year End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year for Non- PEO NEOs ($) | Average Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years for Non- PEO NEOs ($) | Average Fair Value as of Vesting Date of Equity Awards Granted and Vested During Year for Non- PEO NEOs ($) | Average Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested During Year for Non-PEO NEOs ($) | Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non- PEO NEOs ($) | Total – Average Inclusion of Equity Values for Non-PEO NEOs ($) |
2025 | 5,747,017 | 1,974,796 | — | 787,702 | (4,453,777) | 4,055,738 |
As required by Item 402(v) of Regulation S-K, we are providing the following graphs to illustrate the relationship of the
“compensation actually paid” figures that are included in the pay versus performance tabular disclosure above, to (1)
our cumulative TSR and that of the Nasdaq Biotechnology index, (2) our net income, and (3) our net product revenues,
which is our company-selected measure. In addition, the first graph below further illustrates the relationship between
our TSR and that of the Nasdaq Biotechnology Index. As noted above, “compensation actually paid” for purposes of the
tabular disclosure and the following graphs was calculated in accordance with SEC rules and does not fully represent
the actual final amount of compensation earned by or actually paid to our NEOs during the applicable years. The graph
assumes that $100 was invested on January 1, 2021 in each of our common stock and the Nasdaq Biotechnology Total
Return Index and assumes reinvestment of any dividends.
As required by Item 402(v) of Regulation S-K, we are providing the following graphs to illustrate the relationship of the
“compensation actually paid” figures that are included in the pay versus performance tabular disclosure above, to (1)
our cumulative TSR and that of the Nasdaq Biotechnology index, (2) our net income, and (3) our net product revenues,
which is our company-selected measure. In addition, the first graph below further illustrates the relationship between
our TSR and that of the Nasdaq Biotechnology Index. As noted above, “compensation actually paid” for purposes of the
tabular disclosure and the following graphs was calculated in accordance with SEC rules and does not fully represent
the actual final amount of compensation earned by or actually paid to our NEOs during the applicable years. The graph
assumes that $100 was invested on January 1, 2021 in each of our common stock and the Nasdaq Biotechnology Total
Return Index and assumes reinvestment of any dividends.
Relative TSR |
Net Product Revenues |
financial performance measure used by us to link the compensation actually paid to our PEO and non-PEO NEOs, for the most
recently completed fiscal year, to our performance. We have selected net product revenues as this measure.